search
Back to results

Getting Global Rare Disease Insights Through Technology Study (GRIT)

Primary Purpose

Metabolic Disease, Fabry Disease, Gaucher Disease

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Zamplo Digital Health Platform
Sponsored by
M.A.G.I.C. Clinic LTD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Metabolic Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients with a diagnosis of metabolic disease
  • Access to a smartphone/computer with data connection
  • Willingness to devote 10-15 mins of time in a day to log medications and notes
  • Able to speak and write English sufficiently to complete questionnaires

Exclusion Criteria:

  • Insufficient cognitive function to participate in the study
  • The use of any electronic application requires some competency with the software on a cellphone, downloading the application and entering the data. Some patients who are elderly may not be familiar with this technology and would be excluded.

Sites / Locations

  • M.A.G.I.C. Clinic LTDRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

App Group

Placebo Group

Arm Description

Patients in this group are provided with a link to download the application and their application usage is tracked by the clinic.

Patients in this group are not provided with the clinic link to the application.

Outcomes

Primary Outcome Measures

Patient Activation
Patient activation following the use of Zamplo will serve as the primary outcome of interest and will be measured by the Patient Activation Measure (PAM) 13. The PAM 13 shows the degree of the patient's ability to manage their health with confidence by providing a total patient activation score. The survey will be completed by participants of the two groups at baseline and follow-up time-points.

Secondary Outcome Measures

Self-Efficacy for Managing Chronic Conditions (PROMIS)
Manage Medications/Treatment: Self-efficacy is defined as confidence in one's ability to successfully perform specific tasks or behaviors. Self Efficacy for Managing Chronic Conditions assesses confidence in one's ability to successfully perform specific tasks or behaviors related to one's health in a variety of situations. Confidence in managing medication schedules of different complexity.
Patient Satisfaction
This is a survey question asked during Alberta Health Quality Assessments Q11. "Thinking about all of your personal experiences within the past year with the healthcare services in Alberta that we just reviewed, to what degree are you satisfied or dissatisfied with the services you have received?"
Acceptability
The acceptability of Zamplo will be assessed by patients and informal caregivers.

Full Information

First Posted
January 21, 2021
Last Updated
April 6, 2021
Sponsor
M.A.G.I.C. Clinic LTD
Collaborators
Hanalytics Solutions Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04758130
Brief Title
Getting Global Rare Disease Insights Through Technology Study
Acronym
GRIT
Official Title
The G.R.I.T. Study: Getting Global Rare Disease Insights Through Technology
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
August 7, 2020 (Actual)
Primary Completion Date
May 15, 2021 (Anticipated)
Study Completion Date
November 30, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.A.G.I.C. Clinic LTD
Collaborators
Hanalytics Solutions Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This project is a randomized controlled trial to use a mobile health journal, called Zamplo (formerly known as MyHealthJournal or ZoeInsights), to record patient reported outcomes (PROM) in patients with metabolic disorders. The objective of the study is to assess the feasibility, acceptability and potential effectiveness of the Zamplo. The primary hypothesis is as follows: The Zamplo platform will significantly increase patient activation at 6 months post-baseline, defined as an individual's knowledge, skill, and confidence for managing their health and health care. The primary outcome is as follows: Patient activation following the use of Zamplo will serve as the primary outcome of interest and will be measured by the Patient Activation Measure (PAM) 13. The PAM 13 shows the degree of the patient's ability to manage their health with confidence by providing a total patient activation score. Brief Background: This project is a randomized controlled trial to use a mobile health journal, called Zamplo, to record patient reported outcomes (PROM) in patients with metabolic disorders. Zamplo is a software as a service (SaaS) digital platform on both iOS and Android platforms that allows real-time entry of patient symptoms and response to medications. It provides the patients with an interface to see their progress, store questions that they will ask at the next clinic visit, record their health data and use their data to engage in their health outcomes. MAGIC Clinic Ltd., which is the largest clinic in Alberta that manages metabolic disorders such as Fabry disease, Pompe disease, and Gaucher disease, will provide access to Zamplo to patients free-of-charge to evaluate its utility in managing the symptoms of their disease. Brief Study Design: The study is a two-armed randomized controlled design with 1:1 allocation to treatment (Zamplo app group) or control (usual care) arms, with assessments at four time points: baseline, 1 month, 3 months (primary outcome), 6 months and 12 months follow-up post-baseline. This is an open-label trial. The investigators intend to recruit 150 participants in this study, with 75 of them being controls. Inclusion Criteria: Adult patients with a diagnosis of metabolic disease Access to a smartphone with data connection Willingness to devote 10-15 mins of time in a day to log medications and notes Able to speak and write English sufficiently to complete questionnaires. Exclusion Criteria: Insufficient cognitive function to participate in the study The use of any electronic application requires some competency with the software on a cellphone, downloading the application and entering the data. Some patients who are elderly may not be familiar with this technology and would be excluded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Disease, Fabry Disease, Gaucher Disease, Pompe Disease, Mitochondrial Diseases

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
App Group
Arm Type
Experimental
Arm Description
Patients in this group are provided with a link to download the application and their application usage is tracked by the clinic.
Arm Title
Placebo Group
Arm Type
Placebo Comparator
Arm Description
Patients in this group are not provided with the clinic link to the application.
Intervention Type
Other
Intervention Name(s)
Zamplo Digital Health Platform
Intervention Description
This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
Primary Outcome Measure Information:
Title
Patient Activation
Description
Patient activation following the use of Zamplo will serve as the primary outcome of interest and will be measured by the Patient Activation Measure (PAM) 13. The PAM 13 shows the degree of the patient's ability to manage their health with confidence by providing a total patient activation score. The survey will be completed by participants of the two groups at baseline and follow-up time-points.
Time Frame
3 Months post baseline
Secondary Outcome Measure Information:
Title
Self-Efficacy for Managing Chronic Conditions (PROMIS)
Description
Manage Medications/Treatment: Self-efficacy is defined as confidence in one's ability to successfully perform specific tasks or behaviors. Self Efficacy for Managing Chronic Conditions assesses confidence in one's ability to successfully perform specific tasks or behaviors related to one's health in a variety of situations. Confidence in managing medication schedules of different complexity.
Time Frame
3 Months
Title
Patient Satisfaction
Description
This is a survey question asked during Alberta Health Quality Assessments Q11. "Thinking about all of your personal experiences within the past year with the healthcare services in Alberta that we just reviewed, to what degree are you satisfied or dissatisfied with the services you have received?"
Time Frame
3 Months
Title
Acceptability
Description
The acceptability of Zamplo will be assessed by patients and informal caregivers.
Time Frame
3 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients with a diagnosis of metabolic disease Access to a smartphone/computer with data connection Willingness to devote 10-15 mins of time in a day to log medications and notes Able to speak and write English sufficiently to complete questionnaires Exclusion Criteria: Insufficient cognitive function to participate in the study The use of any electronic application requires some competency with the software on a cellphone, downloading the application and entering the data. Some patients who are elderly may not be familiar with this technology and would be excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Desmond Koo
Phone
+1 (403) 888-3278
Email
clinicaltrials@calgarymetabolics.hush.com
Facility Information:
Facility Name
M.A.G.I.C. Clinic LTD
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2M0L6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desmond Koo
Phone
+1 (403) 888-3278
Email
clinicaltrials@calgarymetabolics.hush.com

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://magiccalgary.ca/zoeinsights/
Description
Link to request information about the study

Learn more about this trial

Getting Global Rare Disease Insights Through Technology Study

We'll reach out to this number within 24 hrs